MHRA and NICE open call for evidence on digital mental health resources

The survey runs from 5 November 2026 to 26 February 2027 and will be used to shape the direction of Phase 2 of the Wellcome-funded DMHT programme.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) have launched a call for evidence to evaluate the impact of resources developed under the Wellcome-funded Digital Mental Health Technologies (DMHT) programme.

The survey opened on 5 November 2026 and will remain open until 26 February 2027, the two organisations said.

A deliberately broad audience

The MHRA and NICE are seeking feedback from a wide range of stakeholders, spanning the companies that build digital mental health products, the clinicians and researchers who work with them, and the people the technologies are intended to help.

  • Industry: developers and manufacturers of digital mental health technologies.
  • Professional and policy: healthcare professionals, researchers, policymakers and regulators.
  • Public and carers: people with lived experience of mental health conditions, carers and members of the public.

What the survey is testing

According to the MHRA and NICE, the survey forms part of the programme's Phase 1 evaluation. Its stated aim is to assess how the resources have been received and used across the sector, rather than to collect general opinion on digital mental health tools.

The organisations say they are particularly interested in understanding whether the materials have influenced users' knowledge, confidence, decision-making and professional practice. Taken together, those four measures would indicate whether the outputs are changing how people work with the technologies as intended.

Resources aimed at safe development and adoption

The materials under review were developed to support the safe development, regulation, evaluation and adoption of digital mental health technologies, a category that includes mental health apps and other digital tools. They therefore sit across the product pathway, from building a tool through regulatory and evaluation steps to its adoption in practice.

Findings from the survey will be used to determine whether the Phase 1 outputs have achieved their intended objectives, and will inform the future direction of Phase 2 of the DMHT programme.

Participation open to those who have not used the resources

The MHRA and NICE are encouraging stakeholders to take part whether they have engaged extensively with the existing resources, minimally, or not at all. The breadth of that invitation means responses could reflect very different levels of exposure to the materials.

Feedback from all participants, the organisations say, will help identify strengths, highlight areas for improvement and shape future work aimed at improving the safety and effectiveness of digital mental health technologies.

IP

Ivo Petrov

Ivo Petrov is a clinical laboratory devices analyst covering clinical chemistry, hematology, immunoassay analyzers, PCR systems, and laboratory automation for institutional readers. His coverage examines tests per hour, analytical sensitivity and limit of detection, coefficient of variation, quality-control workflow, and applicable EU IVDR boundaries where a device and assay make those measures relevant. He helps laboratory directors, quality managers, and procurement teams compare throughput, assay fit, service requirements, and total cost of ownership while excluding individualized clinical interpretation and unverified performance claims.